HC Wainwright Predicts Stronger Earnings for Apyx Medical

Apyx Medical Corporation (NASDAQ:APYX) – HC Wainwright upped their FY2026 earnings per share estimates for shares of Apyx Medical in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.21) for the year, up from their previous estimate of ($0.25). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Apyx Medical’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Apyx Medical’s Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.22) EPS.

A number of other research analysts also recently commented on APYX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Finally, Maxim Group initiated coverage on shares of Apyx Medical in a research report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Apyx Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

Apyx Medical Trading Up 0.3%

Shares of NASDAQ:APYX opened at $2.94 on Tuesday. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68. Apyx Medical has a twelve month low of $2.25 and a twelve month high of $5.08. The firm has a 50 day simple moving average of $2.74 and a 200-day simple moving average of $3.58.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $13.29 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nwam LLC acquired a new stake in shares of Apyx Medical in the first quarter valued at approximately $47,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $62,000. AXQ Capital LP acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $78,000. Jefferies Financial Group Inc. acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $110,000. Finally, Squarepoint Ops LLC purchased a new stake in Apyx Medical in the 2nd quarter valued at $144,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

More Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright increased its FY2026 EPS estimate to a loss of $0.21 from $0.25 and its FY2027 estimate to a loss of $0.22 from $0.25. It also raised quarterly forecasts, including Q4 2026 to a loss of $0.04 from $0.06 and Q1–Q3 2027 to losses of $0.06 each from $0.07. The firm reiterated its Buy rating and $7 target. MarketBeat APYX coverage
• Positive Sentiment: Maxim Group was reported to have maintained its Buy rating on APYX, offering additional analyst support, though this item is older than the latest estimate revisions. Maxim Group remains a Buy on Apyx Medical
• Neutral Sentiment: Apyx CEO Charles Goodwin presented at the 2026 UBS Global Healthcare Conference. The provided transcript listings do not identify a specific new announcement or outlook change. UBS conference transcript

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.